Back to Search
Start Over
Perspectives for natural compounds in chemoprevention and treatment of cancer: an update with new promising compounds
- Source :
- Eur J Cancer
- Publication Year :
- 2021
-
Abstract
- Cancer is the second deadliest disease worldwide. Although recent advances applying precision treatments with targeted (molecular and immune) agents are promising, the histological and molecular heterogeneity of cancer cells and huge mutational burdens (intrinsic or acquired after therapy) leading to drug resistance and treatment failure are posing continuous challenges. These recent advances do not negate the need for alternative approaches such as chemoprevention, the pharmacological approach to reverse, suppress or prevent the initial phases of carcinogenesis or the progression of premalignant cells to invasive disease by using non-toxic agents. Although data are limited, the success of several clinical trials in preventing cancer in high-risk populations suggests that chemoprevention is a rational, appealing and viable strategy to prevent carcinogenesis. Particularly among higher-risk groups, the use of safe, non-toxic agents is the utmost consideration because these individuals have not yet developed invasive disease. Natural dietary compounds present in fruits, vegetables and spices are especially attractive for chemoprevention and treatment because of their easy availability, high margin of safety, relatively low cost and widespread human consumption. Hundreds of such compounds have been widely investigated for chemoprevention and treatment in the last few decades. Previously, we reviewed the most widely studied natural compounds and their molecular mechanisms, which were highly exploited by the cancer research community. In the time since our initial review, many promising new compounds have been identified. In this review, we critically review these promising new natural compounds, their molecular targets and mechanisms of anticancer activity that may create novel opportunities for further design and conduct of preclinical and clinical studies.
- Subjects :
- 0301 basic medicine
Cancer Research
Disease
Bioinformatics
Molecular heterogeneity
Treatment failure
Article
03 medical and health sciences
Structure-Activity Relationship
0302 clinical medicine
Drug Discovery
Medicine
Animals
Anticarcinogenic Agents
Humans
Biological Products
Molecular Structure
business.industry
Invasive disease
Plant Extracts
Cancer
medicine.disease
Antineoplastic Agents, Phytogenic
Clinical trial
030104 developmental biology
Oncology
030220 oncology & carcinogenesis
Molecular targets
Margin of safety
business
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Eur J Cancer
- Accession number :
- edsair.doi.dedup.....f399becf582abc8c5cf39e937eb7b0d3